RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels
SEATTLE, Sept. 9, 2021 /PRNewswire/ -- RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company's new Orion spatial biology platform and further global expansion for the Company's portfolio of instruments and consumables.